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ABstrAct
Objectives to characterise the clinical features, 
immune manifestations and molecular mechanisms in a 
recently described autoinflammatory disease caused by 
mutations in TRNT1, a trnA processing enzyme, and to 
explore the use of cytokine inhibitors in suppressing the 
inflammatory phenotype.
Methods We studied nine patients with biallelic 
mutations in TRNT1 and the syndrome of congenital 
sideroblastic anaemia with immunodeficiency, fevers 
and developmental delay (SIFd). Genetic studies 
included whole exome sequencing (WES) and candidate 
gene screening. patients’ primary cells were used for 
deep rnA and trnA sequencing, cytokine profiling, 
immunophenotyping, immunoblotting and electron 
microscopy (EM).
results We identified eight mutations in these nine 
patients, three of which have not been previously 
associated with SIFd. three patients died in early childhood. 
Inflammatory cytokines, mainly interleukin (IL)-6, interferon 
gamma (IFn-γ) and IFn-induced cytokines were elevated 
in the serum, whereas tumour necrosis factor (tnF) and 
IL-1β were present in tissue biopsies of patients with active 
inflammatory disease. deep trnA sequencing of patients’ 
fibroblasts showed significant deficiency of mature 
cytosolic trnAs. EM of bone marrow and skin biopsy 
samples revealed striking abnormalities across all cell 
types and a mix of necrotic and normal-appearing cells. By 
immunoprecipitation, we found evidence for dysregulation 
in protein clearance pathways. In 4/4 patients, treatment 
with a tnF inhibitor suppressed inflammation, reduced the 
need for blood transfusions and improved growth.
conclusions Mutations of TRNT1 lead to a severe and 
often fatal syndrome, linking protein homeostasis and 
autoinflammation. Molecular diagnosis in early life will 
be crucial for initiating anti-tnF therapy, which might 
prevent some of the severe disease consequences.
IntrOductIOn
Recent studies of rare monogenic systemic inflam-
matory diseases have illuminated the complexity of 
immune pathways through the discovery of patients 
who display overlapping features of autoinflam-
mation, autoimmunity and immunodeficiency.1–5 
Sideroblastic anaemia with immunodeficiency, 
fevers and developmental delay (SIFD) is one 
of these disorders caused by recessively inher-
ited hypomorphic mutations in the housekeeping 
gene, TRNT1.6 7 To date, 23 patients have been 
reported, with significant clinical and immunolog-
ical heterogeneity. At the severe end of the spectrum 
are patients with profound anaemia, immunodefi-
ciency, fevers, developmental delay and metabolic 
aberrations leading to high morbidity and mortality. 
At the milder end of the spectrum are patients who 
present with retinitis pigmentosa and moderate 
haematological and immunological abnormalities. 
Although it has been hypothesised that mitochon-
drial dysfunction may play an important role in the 
pathogenesis of SIFD, the molecular mechanisms of 
the disease remain largely unknown.6–14 
TRNT1 is a nuclear gene encoding the enzyme 
tRNA nucleotidyltransferase, CCA-adding, 1 
(TRNT1) that is essential for maturation of cyto-
solic and mitochondrial tRNAs required for protein 
synthesis. The TRNT1 enzyme adds the 3-nt CCA 
sequence at the 3′ end of all precursor tRNAs, 
which is the site of the amino acid attachment cata-
lysed by aminoacyl-tRNA synthetases.15 In addition, 
TRNT1 plays a role in surveillance of tRNA quality 
by selectively marking structurally unstable tRNAs 
for degradation.16 Surprisingly, only one gene has 
been identified in humans. Complete deficiency of 
TRNT1 is embryonic lethal.
Given the ubiquitous expression of TRNT1 and 
its critical function related to protein translation, 
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it is expected that reduced expression of the enzyme will have 
a nearly global effect and lead to a complex phenotype. In this 
study, we aimed to explore the immunological features and 
possible mechanisms of inflammation and to explore the use of 
targeted therapy with cytokine inhibitors.
MetHOds
Patients and healthy controls
All the patients or their parents provided signed informed 
consent to participate in the study, which was approved by the 
NIDDK/NIAMS Institutional Review Board. Patients 2, 4, 5 and 
6 were seen at the National Institutes of Health Clinical Center. 
For all patients, medical records were reviewed, including avail-
able outpatient material. The SI Materials and Methods describe 
the methods used for all the experiments.
results
trnt1 mutations
Independent of the published reports of TRNT1 disease-asso-
ciated mutations, using WES, we identified biallelic loss-of-
function (LOF) mutations in the common gene TRNT1 in two 
affected sisters from a consanguineous Saudi Arabian family 
(patients 1 and 2) and in a single affected child of mixed Euro-
pean ancestry (patient 3). All of them were referred to our clinic 
for evaluation of undiagnosed recurrent fevers (figure 1A,B). 
Patients 1 and 2 were homozygous for the p.His215Arg muta-
tion, whereas patient 3 was compound heterozygous for the 
p.Asp163Val and p.Ile223Thr mutations. Subsequently, we 
identified six additional Caucasian patients, and here we report 
a total of nine patients and eight disease-causing mutations, 
three of which have not been previously associated with SIFD 
(p.Thr110Ile, p.Asp163Val and p.His215Arg) (figure 1A, online 
supplementary table 1). TRNT1 pathogenic variants in patients 
4, 6 and 7 were also found by WES, while patients 5, 8 and 9 
underwent targeted gene sequencing. Two unrelated patients 4 
and 5 shared the same genotype and similar clinical and immu-
nological features (see online supplementary tables 2 and 4). All 
TRNT1 pathogenic variants are either novel or found at a very 
low frequency in the general population (see online supplemen-
tary table 1). All missense disease variants affect evolutionarily 
conserved amino acid residues (figure 1C) and were computa-
tionally predicted to disrupt protein function. Four variants, 
Arg99Trp, Thr110Ile, Asp128Gly and Asp163Val, affect resi-
dues in the active-site domains that are close to the TRNT1 cata-
lytic centre (figure 1D).
clinical manifestations
Patients in this cohort presented with a spectrum of chronic 
disease manifestations including sideroblastic anaemia (SA), 
microcytic anaemia, variable degrees of immunodeficiency, 
vision and sensorineural hearing loss, developmental delay and 
failure to thrive. Detailed clinical characteristics are provided in 
figure 2 and online supplementary tables 2 and 3. Severe bouts 
of inflammation appeared as early as in the first 4–6 weeks of 
life in 7/9 patients, with patients 3, 4 and 5 having evidence 
for persistent systemic inflammation between flares. Although 
the duration of fever in SIFD typically lasts for 5–7 days, in 
patient 5, fevers progressively increased in length, lasting up to 
2 weeks. Mucocutaneous and musculoskeletal manifestations 
occurred frequently, typically in association with fever, and 
included oral ulcers, skin cellulitis, dactylitis and arthralgia or 
arthritis of medium and small joints. As a result, patients are 
often referred to paediatric rheumatologists. Three patients 
experienced recurrent tender subcutaneous nodules. Skin biopsy 
from patient 7 revealed septal panniculitis and neutrophilic infil-
tration extending to the fibrous septa and adipose tissue, find-
ings consistent with erythema nodosum. Patient 5 suffered from 
extensive soft tissue masses that were histologically consistent 
with mononuclear myofasciitis. The need for blood transfusions 
was often increased during fevers. In two patients, bone marrow 
Figure 1 Biallelic mutations in TRNT1 in the NHGRI cohort of patients. (A) Pedigrees of nine patients with SIFD. (B) Schematic representation 
of the exome data filtering approach leading to the identification of TRNT1 as the unique common gene in the first two families. (C) Evolutionary 
conservation of SIFD-associated mutations in this cohort. (D) In silico modelling of TRNT1 mutations based on the crystal structure of human 
TRNT1 (1ou5) (NP_001289875). Residues Arg99, Asp163, Thr110 and Asp128 are located within the head domain of TRNT1 and close to the 
catalytic residues Asp77, Asp79 and Glu121. Residues His215 and Ile223 are located in the neck domain. Lys416 and Ser418 are in the tail domain 
of the enzyme beyond the resolved crystal structure. (The PyMOL Molecular Graphics System, Schrödinger). SIFD, sideroblastic anaemia  with 
immunodeficiency, fevers and developmental delay.
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biopsy revealed signs of haemophagocytosis, more pronounced 
in patient 3 who fulfilled part of the criteria for acquired lympho-
histiocytosis syndrome, including neurological involvement (see 
online supplementary table 2). Finally, two patients experienced 
unprovoked recurrent thromboembolic events and these haema-
tological findings have not been previously reported in SIFD.
Patient 1 died of multiorgan failure at the age of 7 years during 
a sepsis-like culture-negative febrile episode. Patient 3, who had 
prominent neurological deficits and severe B cell immunodefi-
ciency, died at the age of 3 years, 92 days post peripheral blood 
stem cell transplant (see online supplementary table 2). Patient 
7, who underwent a splenectomy for transfusion-dependent 
anaemia, died at the age of 9 years from Staphylococcus aureus 
sepsis. Her sibling, patient 6, aged 26 years, has relatively mild 
disease compared with other patients in the cohort (see online 
supplementary table 3).
Immune system dysregulation
In this cohort, hypogammaglobulinaemia was detected in 7/9 
patients. Persistent B cell lymphopenia was observed in four 
patients (see online supplementary tables 2–5). Flow cytometric 
analysis of bone marrow aspirate showed a significant increase 
in the percentage of immature B cells (CD10+/CD20−) and a 
marked decrease in mature CD10−/CD20+ B cells (see online 
supplementary figure 1), findings suggestive of abnormal B cell 
maturation as a probable cause of B cell lymphopenia.6 17
T cell numbers were mostly normal or in the low to normal 
range. However, a decreased CD4/CD8 ratio was observed in 
two patients. Three patients had abnormal findings on lympho-
cyte proliferation assays (online supplementary tables 4 and 
5). Other abnormalities included decreased numbers of mono-
cytes and neutrophils, circulating bands and toxic granulosis of 
neutrophils and a higher numbers of double negative T cells in 
two patients (see online supplementary tables 2, 3 and 6).
In the majority of patients, natural killer (NK) cell numbers 
were in the low to normal range. Multicolour flow cytometry 
showed a trend for NK cell activation in the patients (n=3) 
compared with age-matched healthy controls (n=3), based on 
higher frequency of surface activating and cytotoxic receptors. 
The differences did not reach statistical significance, perhaps 
due to small sample size (see online supplementary figure 2A–C). 
Similarly, we observed a trend for decreased IFN-γ production in 
NK cells, despite preserved cytotoxicity, a phenomenon that has 
been described in chronic viral infections (see online supplemen-
tary figure 2D).18
All patients with hypogammaglobulinaemia (7/9) received IgG 
replacement therapy since diagnosis. Serious bacterial or viral 
infections remained infrequent and were likely a consequence of 
the underlying immunodeficiency and/or treatment with immu-
nosuppressive therapy (see online supplementary tables 2 and 3).
Inflammatory signature
High acute-phase reactants, proinflammatory cytokines and 
chemokines were documented in two patients who had clinically 
active disease at the time of sampling. Serum cytokine profiling 
in patient 4 at two different time points (CRP levels of 200 
Figure 2 Clinical findings of the NHGRI cohort of patients with SIFD. (A) Iron staining of patient 2 bone marrow aspirate showing ring sideroblasts 
(that represented more than 50% of erythroid precursors) (black arrows) and increased iron staining. (B) Abnormal findings in the cerebrum of patient 
3 by fluid-attenuated inversion recovery (FLAIR)  MRI of the brain. The image shows bilateral cerebral atrophy (yellow arrows), enlarged ventricles 
(white arrows) and extensive leukomalacia (red arrow heads). (C) H&E staining of rectosigmoid colon biopsy in patient 3 showing acute focal 
inflammation. (D) Splenomegaly in patient 2. (E) Knee effusion in patient 5. (F) Phagocyte (arrow) on bone marrow aspirate smear of patient 4. (G) 
Neutrophil with toxic granules in peripheral blood smear of patient 4. SIFD, sideroblastic anaemia  with immunodeficiency, fevers and developmental 
delay.
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mg/L and 133 mg/L each, normal <3 mg/L) showed high levels 
of IL-6, IL-12p40, IL-18, IFN-γ and the IFN-induced chemok-
ines IP-10 and MIG (figure 3A). Postmortem analysis of plasma 
samples from patient 3 showed a similar cytokine profile, in 
particular high levels of IL-6, IL-18, IP-10 and MIG (figure 3B). 
The same patients had elevated levels of endogenous inhibitors 
of TNF, soluble TNF receptors 1 and 2, as further evidence of 
ongoing inflammation. Levels of anti-inflammatory cytokines 
were not significantly elevated. The assessment of cytokine 
production in stimulated whole blood cells or peripheral blood 
mononuclear cells (PBMCs) (with TLR-agonists, mitogens, TNF 
and IFNγ) from four patients showed no statistically signifi-
cant differences compared with healthy control cells (data not 
shown).
electron microscopy
EM of bone marrow and skin biopsies showed a mixture of 
damaged, necrotic and normal-appearing cells. There was signif-
icant cellular degeneration with mitochondrial damage and 
numerous autophagosomes across all cell types (figure 4).
defect in maturation of trnAs
We hypothesised that hypomorphic TRNT1 mutations will nega-
tively affect the expression of mature cytosolic tRNAs in addi-
tion to previously reported mitochondrial tRNAs. We performed 
deep resequencing of mature tRNAs isolated from patient-de-
rived fibroblasts (n=2) and healthy controls (n=3). Out of 227 
tRNAs expressed in our dataset, 182 (80 %) were reduced in the 
patients compared with healthy controls. On average, the tRNA 
expression in the patients was 1.6-fold lower, a difference that 
was statistically significant (figure 5A).
Increased reactive oxygen species (rOs) production in 
patients’ fibroblasts
Damaged mitochondria are a major source of intracellular ROS, 
which is a known trigger of inflammatory responses. Given 
the extensive mitochondrial abnormalities in patients’ cells 
(figure 4A), we measured ROS production in patients’ (n=3) 
and controls’ (n=2) fibroblasts. The number of live cells was 
slightly decreased in patients’ fibroblasts cultured for 72 hours, 
compared with controls (online supplementary figure 3A). 
The ROS production per live cells was higher in patients than 
controls (online supplementary figure 3B).
ROS accumulation is a known trigger of inflammasome-me-
diated pathways, including the NLRP3 inflammasome.19 20 We 
observed a higher production of IL-1β in the supernatant of 
stimulated monocyte-derived macrophages from patient 4 and 
in colon biopsy tissue from patient  5 by immunohistochem-
istry (online supplementary figure 4A, figure 6C). To further 
examine the effect of TRNT1 deficiency in myeloid cells, we 
knocked down TRNT1 in cultured human monocytic THP-1 
cells. Small interfering RNA-mediated depletion of TRNT1 led 
to a significantly higher secretion of IL-1β in unstimulated and 
lipopolysaccharides (LPS) stimulated cells (online supplemen-
tary figure 4B,C). This effect was reversed in the presence of 
the NLRP3 inflammasome-specific inhibitor MCC950 (online 
supplementary figure 4C).
deregulation of protein degradation pathways
Damaged mitochondria and proteins need to be efficiently 
removed by protein degradation pathways to prevent cellular 
stress and death. Given the evidence of necrosis and impaired 
protein synthesis in mutant cells, we investigated the function 
and efficiency of the ubiquitin-proteasome system (UPS) and the 
autophagy-lysosome system, which are responsible for removal 
and recycling of cell debris and damaged proteins.
Proteins that are targeted for degradation by UPS are marked 
by polyubiquitin lysine 48 (K48) chains. TNF-stimulated patients’ 
fibroblasts showed accumulation of high-molecular weight K48 
Ub aggregates following treatment with the proteasome inhibitor 
MG132, compared with healthy control fibroblasts (figure 5B). 
Proteasome dysfunction activates autophagy.21 22 On induc-
tion of autophagy and formation of autophagosomes, LC3B-I 
protein converts to LC3B-II protein and the ratios of LC3B-II 
to LC3B-I and LC3B-II to actin are used to monitor auto-
phagic activity. TNF-stimulated and MG132-treated patients’ 
Figure 3 Inflammatory signature in patients with SIFD. (A) Serum cytokine and chemokine levels from patient 4 compared with paediatric healthy 
controls. For patient 4, each symbol represents measurements of serum samples collected during two independent flares (CRP levels 133 mg/L and 
220 mg/L, respectively, normal values <3 mg/L). Forty-eight cytokines were measured by bead-based immunoassay as described in Material and 
Methods. Proinflammatory cytokines IL-6, IL-12p40, IL-18, IFN-γ and IFN-induced chemokines (IP10 and MIG) and levels of circulating soluble TNF-R1 
(sTNF-R1) and TNF-R2 (sTNF-R2) were at least 10 SD higher in the patient compared with the average concentration of the 11 healthy controls. (B) 
Elevated levels of cytokines and chemokines, as shown for P4 in panel A, in postmortem plasma sample from patient 3 and a healthy control.
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fibroblasts displayed decreased LC3B-I to LC3B-II conversion 
compared with controls suggesting an impairment of autophagy 
(figure 5C). Under conditions of starvation that induces auto-
phagy and chloroquine treatment that blocks the degradation 
of autophagosomes, both patient and control cells upregulated 
the autophagic activity as shown by increased LC3B-II levels 
(online supplementary figure 5A,B middle panels). However, 
mutant cells showed deficient clearance of the ubiquitin-scaffold 
protein p62 (sequestosome 1), which is a substrate for both auto-
phagy and UPS (online supplementary figure 5A,B, top panels). 
This indicates a general inefficiency of TRNT1-deficient cells to 
upregulate protein clearance pathways under stress conditions.
treatment with tnF inhibitors
Four patients have been treated with TNF inhibitors and showed 
steady improvement of clinical and laboratory parameters. 
Patient 5 was started on infliximab 12 years ago, patients 2 and 
4 were started on etanercept following their molecular diag-
nosis, approximately 3 years ago, and patient 9 about 18 months 
ago. Anti-TNF therapy has been efficacious in suppressing fevers 
and normalising the inflammatory biomarkers (figure 6A,B). 
Immunohistochemical staining of colon tissue biopsies of patient 
5 showed resolution of inflammatory infiltrates, primarily of 
neutrophils and macrophages, and reduction in staining for 
TNF and IL-1β (figure 6C). The frequency of blood transfu-
sions in patients 2 and 4, both with a history of severe anaemia, 
decreased dramatically since the initiation of etanercept. Patient 
9, who was entirely total parenteral nutrition (TPN) dependent, 
although on a suboptimal dose of etanercept, experienced a 
substantial improvement in enteropathy, which resulted in TPN 
wean and enteral feeding, and fewer blood transfusions.
We analysed the gene expression profile in whole blood 
samples of patient 4 before and after treatment with etaner-
cept. We identified a set of 234 differentially expressed genes 
(DEGs) before treatment, compared with three age-matched 
healthy controls, that changed expression by at least two-fold 
following treatment with etanercept (online supplementary 
figure 6A). Pathway analysis assigned these DEGs into 52 statisti-
cally significant canonical pathways (online supplementary table 
7 and supplementary figure 6B). They include pathways that are 
known to be regulated by TNF, such as leucocyte adhesion and 
trafficking, and endothelium activation.
Zebrafish model
CRISPR-mediated mutagenesis in zebrafish with complete LOF 
mutations recapitulated several phenotypes observed in patients 
with SIFD and confirmed the critical role of TRNT1 in develop-
ment (online supplementary figures 7 and 8). The trnt1−/− (null) 
zebrafish develop normally for the first 4 days as they can rely 
on the maternal sources of trnt1 present in the fertilised egg, but 
they all die of multisystem defects by nine days post fertilization 
(dpf) (online supplementary figure 7A).
dIscussIOn
SIFD is a distinct autoinflammatory disease caused by mutations 
in the constitutively expressed enzyme, TRNT1, with a critical 
role in tRNA biogenesis. With the exception for SIFD and meva-
lonate kinase deficiency, other autoinflammatory diseases are 
caused by mutations in genes that are preferentially expressed in 
haematopoietic cells. The full continuum of clinical manifesta-
tions associated with decreased TRNT1 function is still emerging.
Figure 4 Ultrastructural findings of extensive cellular degeneration and necrosis. (A) Mitochondrial degeneration, from left to right: monocyte in 
patient 4 bone marrow (BM) with numerous degenerated mitochondria (white arrows); lymphocyte in patient 4 BM with coexistence of two normal 
mitochondria (M) and two abnormal, degenerate mitochondria (DM); monocyte in patient 6 BM with accumulation of lipid droplets (L), degenerate 
mitochondria (DM) (white arrows), nuclear envelope gaps (white arrowheads, N=nucleus). (B) Increased autophagosomes, from left to right: skin 
fibroblast in patient 6 with multiple autophagosomes (white arrows), degenerated mitochondrion (white arrowhead); degenerate fibroblast in 
patient 6 with pyknotic nucleus (N), extranuclear chromatin vesicles (CV), autophagosomes (A) and degenerate mitochondria (M). (C) Necrotic cells 
and debris in patient 4 BM (left and middle panel); blood vessel in P4 BM showing abnormal, degenerate endothelial cell (E), with thin, rough margins 
(white arrowheads), autophagosomes within serum (white arrows), vessel wall breakage and serum leakage (white circle) (M=monocyte).
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In this report, we extend the mutational spectrum and pheno-
typic attributes of SIFD, with a special emphasis on the immune 
and inflammatory manifestations. Clinical variability has been 
observed in this cohort and previously reported cases.6–14 
Although congenital SA is one of the hallmarks of the disease, in 
three of our patients with chronic microcytic anaemia, SA was 
appreciated following the molecular diagnosis of the disease and 
re-evaluation of the bone marrow. Two of the patients carried 
a diagnosis of CVID, and notably the two siblings from Saudi 
Arabia had no evidence of B cell immunodeficiency. A signifi-
cant clinical variability was observed among the affected siblings 
(families 1 and 5), which suggests a role for other modifying 
genes.
A previous study in SIFD demonstrated a deleterious effect of 
the TRNT1 deficiency on maturation of mitochondrial tRNAs.8 
This is the first report to show a more global reduction in the 
expression of mature cytosolic tRNAs. Substantial mitochon-
drial damage and mitochondrial dysfunction in SIFD has been 
reported previously and in this study.7 8 11 12 Consistent with this 
cellular phenotype, we observed a higher spontaneous produc-
tion of ROS in cultured patient fibroblasts. We also showed that 
TNRT1-deficient macrophages had increased production of 
IL-1β that was NLRP3 dependent.
The maintenance of protein homeostasis is essential to 
preserve cell functionality and survival. Rapid adjustments in 
protein translation are critical for cell survival and adaptation to 
stress. We showed that under stress conditions, mutant patient 
cells fail to upregulate protein clearance pathways. Perturba-
tions in proteostasis are known to elicit activation of the innate 
immune system.23
EM in an actively inflamed patient was striking for the pres-
ence of necrotic and necroptotic cells, vascular leakage and 
extensive intercellular debris. Studies of cell death and inflamma-
tory response continue to expand at the cellular and molecular 
levels. Dying and necrotic cells release an array of DAMPs and 
proinflammatory cytokines, such as IL-6 and IL-1, that increase 
chemoattraction of phagocytes to the site of necrosis, causing acti-
vation of inflammatory cascades.24–26 TNF is a potent stimulator 
and, after binding to TNFR1, can either stimulate downstream 
proinflammatory and survival signalling, that is, NF-kB pathway, 
or trigger cell death pathways and further perpetuate the inflam-
matory response.26 27 It is also possible that the accumulation 
of unprocessed/misfolded proteins causes endoplasmatic retic-
ulum (ER) stress that activates the signalling unfolded protein 
response (UPR) network in TRNT-1-deficient cells, making them 
susceptible to TNF production. Although TNF levels were low in 
peripheral blood or supernatants of stimulated PBMCs, TNF was 
present in lesional biopsies along with inflammatory infiltrates 
consistent primarily of neutrophils and macrophages. Further 
studies are needed to identify TNF producing cells in SIFD.
Figure 5 Decreased mature tRNAs and proteostasis dysregulation in patients’ cells. (A) Defect in maturation of cytosolic tRNAs in patients’ 
fibroblasts. Briefly, tRNAs were purified from total RNA from patient (n=2) and healthy control (n=3) fibroblasts to prepare a small RNA library, 
followed by Illumina sequencing as outlined in Materials and Methods. Small RNA reads were aligned to the human genome and expression values 
for mature tRNAs, expressed in our dataset (n=227), were calculated as described in Materials and Methods. Left panel: plots show the density of the 
average expression of mature tRNAs in patients versus controls. Right panel: frequency of mature tRNAs in patients (n=2) relative to healthy controls 
(n=3). The x-axis of the histogram represents log2 ratio intervals and the y-axis represents the corresponding number of mature tRNAs in each ratio 
range. Statistics: one-sample Wilcoxon signed rank test. (B) Increased intracellular K48 ubiquitin levels and defects in autophagosome formation in 
mutant fibroblasts following stimulation with TNF and treatment with proteasome inhibitor MG132. Cultured fibroblasts from patients (n=2) and 
healthy controls (n=4) were detached from plates and treated with TNF with or without the proteasome inhibitor MG132 for 3 hours. Cells were lysed 
and immune-precipitated with antibodies against ubiquitin, and then blotted with specific antibody against K48-specific ubiquitin. (C) Bands in the 
immunoblots were quantified by Quantity One (Bio-Rad) and the ratio of LC3B-II/LC3 B-I is shown in bar graphs. TNF, tumour necrosis factor.
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Most patients are treated symptomatically, including red 
blood cells (RBC) transfusions, IgG replacement therapy and 
steroids, while the disease mortality remains high (median 
survival 48 months).6 This is the first report describing the clin-
ical benefits of anti-TNF therapy for patients with SIFD. The 
dramatic response to the treatment with TNF inhibitors argues 
that TNF-dependent mechanisms have a major role in the patho-
genesis of inflammation in SIFD. Our data suggest that TNF 
inhibitors suppress proinflammatory cytokines in the tissue and 
blood and decrease tissue inflammatory infiltrates. Two patients 
in this cohort had inefficient clinical response to treatment with 
IL-1β inhibitors (patient 4 and  patient 8), similar to a single case 
reported previously.6 This indicates that IL-1 is contributing but 
not a major cytokine driving inflammation in SIFD.
The substantial decrease in requirement for blood transfu-
sions following treatment with TNF inhibitors is likely related 
to improvements in anaemia of chronic disease. IL-6 is known to 
induce production of hepcidin, which in turn inhibits the differ-
entiation of erythroid cells and decreases iron absorption.28 
However, a chronic microcytic anaemia due to congenital SA 
persists in SIFD. Although hematopoietic stem cell transplanta-
tion (HSCT) was successful in ameliorating fevers and anaemia 
in a single patient, it is associated with increased risk for other 
complications.6 It is likely that TNF inhibitors do not have a 
direct effect on other TNF-independent disease processes, such 
as protein synthesis and turnover, although additional studies 
are required.
Collectively, our findings highlight the complexity of immune 
responses arising from mutations in TRNT1  and connect dysreg-
ulation in protein homeostasis to inflammation. Most important, 
our study is the first to report a new therapy for patients with 
SIFD, which can be especially beneficial if initiated early in life.
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